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Abstract
Purpose of Review This review was designed to revaluate the
androgen role on the mechanisms of hypertension and cardio-
vascular risks in both men and women. Sex steroids are in-
volved in the regulation of blood pressure, but pathophysio-
logical mechanism is not well understood. Androgens have an
important effect on metabolism, adipose and endothelial cell
function, and cardiovascular risk in both men and women. A
focal point in this contest is represented by the possible gender-
specific regulation of different tissues and in particular of the
adipose cell. Available data confirm that androgen deficiency
is linked to increased prevalence of hypertension and cardio-
vascular diseases. Adipocyte dysfunction seems to be the main
involved mechanism. Androgen replacement reduces inflam-
mation state in man, protecting by metabolic syndrome pro-
gression. In women, androgen excess has been considered as
promoting factor of cardiovascular risk. However, recent data
suggest that excessive androgen production has little effect per
se in inducing hypertension in young women of reproductive
age. Also in postmenopausal women, data on relative andro-
gen excess and hypertension are missing, while adrenal andro-
gen deficiency has been associated to increased mortality.
Recent Findings Molecular mechanisms linking androgen dys-
regulation to hypertension are almost Unknown, but they seem
to be related to increased visceral fat, promoting a chronic in-
flammatory state through different mechanisms. One of these
may involve the recruitment and over-activation of NF-kB, a
ubiquitous transcription factor also expressed in adipose cells,
where it may cause the production of cytokines and other im-
mune factors. The NF-kB signalling pathway may also influ-
ence brown adipogenesis leading to the preferential enlargement
of visceral adipocytes. Chronic inflammation and adipocyte dys-
function may alter endothelial function leading to hypertension.
Summary Both in men and in women, particularly in the post-
menopausal period, hypoandrogenism seems to be a major
determinant of the increased prevalence of hypertension. The
relationship between androgen signalling and NF-kB might
explain the pathophysiological mechanism leading to the de-
velopment of endothelium dysfunction and hypertension.
Keywords Androgens . Androgen receptor . Adipokines .
NF-kappaB . Endothelial dysfunction .Metabolic syndrome .
Cardiovascular disease . Hypertension . Obesity . Brown
adipose tissue . PCOS
Introduction
In the last few years, interest in the role played by sex gender on
the regulation of metabolic homeostasis, blood pressure, and
cardiovascular disease (CVD) has been growing. Men typically
develop CVD earlier than women [1]. The sexual dimorphism
begins at the time of puberty and continues through the adult age
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until post-menopause, when women have higher blood pressure
than age-matched men [2–4, 5•].
In this short review, we will focus on the possible different
effects by sex of androgens on hypertension. It has been re-
ported that this sexual dimorphism may depend on different
responses in men and women to androgens. However, recent
evidence suggests that the effects of androgens on hyperten-
sion may be similar in males and females. Finally, we will
review the mechanisms by which androgens may determine
hypertension. In particular, we will discuss new information
showing an important interaction of androgens with factors
involved in endoplasmic reticulum (ER) oxidative stress and
NF-kB activation, which play pivotal roles in the pathogenesis
of metabolic syndrome and by this way may induce hyperten-
sion [6–9]. Moreover, the ability of androgens to modulate
endothelial cell function, through genomic or non-genomic
signaling pathways, will be examined [10].
Androgens and Hypertensive Risk in Males
A direct effect of androgens on promoting hypertension has
been hypothesized [1]. Animal studies suggested that andro-
gens could promote hypertension by stimulating sodium reab-
sorption via the proximal tubule of the kidney [11] or by
increasing angiotensinogen synthesis in the kidney [12, 13].
Consistent with that, it was reported that androgens probably
stimulate oxidative stress and increase endothelin production,
thereby promoting renal vasoconstriction [14] and resulting in
hypertension in men but not in women [15].
However, in the last few years, several studies have shifted
attention to the effect of low androgen levels on hypertension.
In fact, it has been demonstrated that men with free testoster-
one levels in the lowest quartile had a 24% greater risk for all-
cause mortality due to ischemic heart disease [16].
Specifically, in old men, total testosterone levels are inversely
associated with systolic blood pressure and increased risk of
death over the subsequent 20 years, independently from other
risk factors and pre-existing health conditions [17].
Furthermore, lower testosterone levels predict cardiovascular
events in older men, such as stroke and transient ischemic
attack, and are associatedwith higher cardiovascular and over-
all mortality. Androgen levels are actually decreased in men
with chronic diseases, including hypertension, obesity, heart
disease, chronic kidney disease, and metabolic syndrome [18].
These findings have led to the proposition that in middle-
aged and older men, lower testosterone levels are associated
with conditions that predispose to CVD, such as hypertension
[19]. Many investigators have suggested that lower testoster-
one blood levels are not just a consequence of the chronic
disease but actually contribute to disease progression [20]. In
addition, androgen replacement reduces systolic and diastolic
blood pressure [21–23], while androgen therapy worsens hy-
pertension and CVD risk inmenwith no testosterone deficien-
cy [24]. Finally, it has been shown that androgens increase
blood pressure in hypertensive non obese rats. [25].
Overall, these data suggest that in men, androgen deficien-
cy may worsen cardiovascular physiology by several mecha-
nisms. One of these effects is the increase in blood pressure.
Hypoandrogenism, Blood Hypertension,
and Metabolic Syndrome in men
Several studies have demonstrated a link between androgen
deficiency, hypertension, and metabolic syndrome. It has been
hypothesized that hypogonadism may increase hypertension
risk by promoting metabolic syndrome (MetS). In fact, andro-
gen deficiency is particularly common in men with MetS
[26••], and hypoandrogenism may be an additional feature
of this disease [27•]. Finally, men with prostate cancer who
undergo long-term androgen deprivation therapy have signif-
icantly higher rates of MetS [28, 29••, 30].
The nature of the link between androgen deficiency and
MetS is likely to be multifactorial and different among individ-
uals. Diminished testosterone synthesis may be determined by
metabolic syndrome through several mechanisms, including a
low-grade inflammatory state and increased visceral fat, both
important features ofMetS. Androgens have anti-inflammatory
activity, and hypogonadal men treated with androgen replace-
ment exhibit a significant reduction in inflammatory cytokine
levels [31]. It is also known that visceral adiposity may reduce
sex hormone binding globulin levels and luteinizing hormone
(LH) amplitude, thereby influencing bioavailable testosterone
in obese men. Indeed, abdominal obesity has been associated
with low testosterone (T) in both cross-sectional and longitudi-
nal studies, and low T concentration correlates with greater
visceral fat accumulation. Increased central fat depots may con-
tribute to hypogonadism through increased aromatase activity,
resulting in a higher conversion of T to estradiol (E2) [32]. Fat
cells also synthesize leptin and inflammatory cytokines, which
have been inversely associated with testosterone levels, per-
haps through an inhibitory effect on the production of LH [33].
On the other hand, androgen deficiency may directly con-
tribute to obesity and development of MetS by promoting the
production of fat cells. Testosterone promotes lipolysis and
reduces fatty acid synthesis, and animal models have shown
that T deficiency decreases lipolysis [34••].
Thus, the available evidence strongly suggests that in men,
there is a strict bidirectional relationship between fat accumu-
lation and T deficiency [35], and this may be a major mecha-
nism by which androgens influence blood pressure.
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Hyperandrogenism and Hypertension Risk in Young
Women with Polycystic Ovarian Syndrome
Young women typically have a lower hypertension rate than
age-matched men [36]. The sex differences in blood pressure
control may be explained by the different hormonal status but
mainly by the presence in young women of elevated estrogen
levels that protect against endothelial dysfunction and CVD. It
is known that E2 has vasodilator function by increasing endo-
thelial nitric oxide synthase [37] and angiotensin converting
enzyme 2 (ACE2) and down-regulating ACE and AT1 recep-
tor [38]. Estradiol is also a modest antioxidant [15]. Moreover,
animal studies suggest that estrogens protect against hyperten-
sion by reducing sympathetic outflow [39].
A higher prevalence of hypertension in young women with
elevated androgen levels has been reported and could suggest
that elevated androgens induce an increased risk for hyperten-
sion [40•]. However, data from women with polycystic ovary
syndrome (PCOS), the most common cause of androgen ex-
cess in women, seem to indicate a different pathogenesis of
hypertension in these subjects. PCOS is a complex disorder
that is often associated with metabolic alterations of insulin
resistance, increased susceptibility to type 2 diabetes, central
obesity, and elevated CVD risk [41]. Prevalence of hyperten-
sion in young PCOS women aged 18–35 years is increased
(7.3% of patients with the classic severe form) and is higher
than that reported in the general female population of similar
age [42, 43•]. Thus, analogously on what happens in men
(24), in women, a link between androgen excess and blood
pressure dysregulation has been proposed.
However, most evidence suggests that in PCOS, the elevat-
ed hypertension risk is determined by the metabolic alter-
ations. In fact, PCOS is a very heterogeneous disorder with
different subgroups of patients with different prevalence of
hypertension [44, 45]. All data reporting increased prevalence
of hypertension refer to patients with the severe phenotype
(classic PCOS or phenotype A and B) that is associated with
insulin resistance and central obesity. Patients with mild phe-
notypes (phenotypes C and D) do not have an increased risk of
hypertension [45]. In particular, PCOS patients with pheno-
type C have increased androgen production but no increased
prevalence of hypertension. Interestingly, these same patients
have a low prevalence of insulin resistance andMetS and have
a body weight lower than PCOS patients with the classic phe-
notype [45].
It may be concluded that in PCOS, the increased risk of
hypertension is linked to the metabolic dysfunction with
mechanisms that may be similar to that found in hypogonadal
men. The adipocyte dysfunction likely plays a pivotal role in
the relationship between hyperandrogenemia and CVD risk
[19]. In fact, an important hallmark of PCOS women with
the severe phenotype is the excess of visceral adipose cells
that increase the release of inflammatory cytokines and de-
crease production of adiponectin, thereby promoting endothe-
lial dysfunction and hypertension [46]. The adiponectin/leptin
and adiponectin/resistin ratios may predict MetS and hyper-
tension in women with PCOS [47•].
Overall, in young women, androgens have a small role per se
in increasing blood pressure andmay participate in the pathogen-
esis of hypertension only by contributing to insulin resistance
and/or adipocyte excess and dysfunction. On the other hand,
hyperinsulinemia and adipocyte dysfunction further increase an-
drogen levels, promoting a vicious cycle which ensures an in-
flammatory state, MetS, and increased CVD risk.
Androgens and Hypertension in Postmenopausal
Women
The sexual dimorphism on blood pressure control begins at
puberty and persists until after menopause, when women have
higher blood pressure than age-matched men. The incidence
of CVD-related deaths is generally higher in women than men
[48, 49], and in Europe, as in the rest of the world, 25% of
postmenopausal women are hypertensive [50].
Postmenopausal changes in estrogen/androgen ratio that
induce a relative androgen excess have been proposed as im-
portant factors in the higher prevalence of hypertension [36] in
older women. Initial studies reported that both E2 and T pro-
duction decrease after menopause, but T increases progres-
sively until 70 years of age, when androgen production is
similar to that of premenopausal women [51].
However, the concept of a relative hyperandrogenism in
postmenopausal women has been challenged by a better un-
derstanding of adrenal and ovarian androgen secretion.
Adrenal androgens start decreasing by the age of 25–30 years,
and in postmenopausal women, their levels are at least 50%
lower than in reproductive women of younger age [52].
Ovarian androgens start decreasing later at an age of 35–
40 years and during the postmenopausal period are about
30% lower than in young reproductive age [53–55] More
studies are needed to better explain hypertension prevalence
in postmenopausal women, but it has to be remembered that in
aging women, as in men, very low dehydroepiandrosterone
sulfate (a main adrenal androgen) levels have been associated
with increased mortality [56••].
Quite possibly, the relative deficiency of estrogen that is
observed after menopause participates in metabolic dysfunc-
tion and deposition of visceral (and ectopic) fat that is ob-
served after menopause. In some ways, these phenomena are
more evident in women than in men because of the important
effect of estrogen reduction.
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Androgen Deficiency, Metabolically Active Obesity,
and Hypertension
As we have discussed, androgens exhibit beneficial effects on
cardiovascular function, and growing evidence suggests that this
non-classic effect of androgens is largely mediated by the pre-
vention of adipocyte dysfunction. As we have reviewed in a
previous paper [19], adipocyte dysfunction probably represents
the main mechanism inducing the endothelial alterations that are
typical of hypertension and cardiovascular diseases of obese
subjects.
While liver accumulation of free fatty acids (FFA) released
by visceral fat is generally considered the main determinant of
insulin resistance in obesity, other mechanisms, and in partic-
ular dysfunctional regulation of adipokines, may be equally or
more important to explain insulin resistance in the obese state.
In this process, the reduction of adiponectin levels seems to
play an essential role. Because adiponectin is mainly produced in
the subcutaneous fat [57], it has been hypothesized that increased
production of cytokines inside the visceral and ectopic fat is the
mechanism that inhibits subcutaneous production of adiponectin.
The process may be initiated by increased death of adipose cells
consequent to excessive enlargement of visceral and intramuscu-
lar adipose cells. It is followed by colonization and activation of
macrophages and by increased production of several inflamma-
tory factors mainly cytokines but also some adipokines (resistin,
visfatin) [19].
Other adipokine changes are part of the adipocyte dysfunction
and may be particularly important for inducing hypertension. In
particular, increased leptin may induce hypertension by promot-
ing sympathetic nervous system overactivity while reduced
omentin may have a permissive role on atherogenesis.
Molecular Mechanisms Linking Androgen
Deficiency to Hypertension. The Role
of the Interaction Between Androgen Receptor
and NF-kB
The molecular mechanisms linking androgen deficiency to
adipocyte dysfunction are largely unknown. However, two
main mechanisms may be hypothesized.
Because most hypogonadic men and women have in-
creased adipose tissue mainly in visceral and intramuscular
locations, it may be thought that in conditions of excessive
energy supply, androgens promote adipocyte multiplication in
subcutaneous regions while in conditions of androgen defi-
ciency, lipids are accumulated mainly in visceral areas by an
increased in the size of adipocytes. Excessive adipocyte size
may be followed by increased cellular death, macrophage ac-
tivation, and cytokine production. The final consequence is
obesity, chronic inflammation, and atherogenesis.
However, androgen deficiency may promote inflammatory
and immune responses inside adipose tissue by alternativemech-
anisms. In fact, it has been shown that androgen receptor (AR)
deficient mice have higher blood pressure compared to wild type
[58]. The AR seems to interact with several factors having an
important role in the regulation of immune and inflammatory
response and in cell growth and differentiation.
One of these factors, nuclear factor κB (NF-kB) [59–61], is a
dimer composed of nearly all combinations of the NF-κB family
members p65/RelA, RelB, c-Rel, NF-κB1/p50, or NF-κB2/p52
and expressed as RelA/p50 heterodimeric complex in many tis-
sues but mainly in liver and adipose cells [62••]. NF-kB (see
Fig. 1) may play an important role in the inflammatory activation
and progression caused by adipocyte dysfunction [63]. NF-kB
along with other factors like p38MAPK and ERK1/2 has an im-
portant role in regulating immune responses inside the adipose
cells [62••]. Activation of the NF-kB signaling pathway may also
determine dysregulation in the liver and central nervous system
(CNS), as the mediobasal hypothalamus controls energy balance,
appetite regulation, and food intake. IKKβ, one of the most im-
portant activators ofNF-kB, is constitutively expressed in theCNS
of mice exposed to a high-fat diet, blocking leptin and insulin
signaling and promoting IL-6 secretion and JNK pathway signal-
ing. Likewise, constitutively active IKKβ alters insulin-signaling
in hepatocytes, contributing to systemic insulin resistance and glu-
cose intolerance. In fact, NEMO (IKKγ) deficient mice are
protected from diet-induced obesity, glucose intolerance, and insu-
lin resistance, suggesting that NEMO expression is required for
development of obesity-induced insulin resistance. Moreover,
studies suggest that during the onset of insulin resistance, NF-kB
promotes β cell growth to compensate for the systemic lowered
response to insulin [64]. Besides being involved in insulin resis-
tance development and progression, NF-kB proinflammatory
pathways contribute to endothelial dysfunction and vascular dis-
ease associated with MetS [62••]. Indeed, many genes driving the
formation of atherosclerotic plaques are NF-kB targets. TheNFkB
nuclear absence inmacrophages composing atherosclerotic lesions
[65] and the abrogated expression of adhesion molecules as
Fig. 1 Effect of androgen deficiency on increasing risk of metabolic
syndrome and cardiovascular disease. Both in men and in post-
menopausal women, when the protective estrogen effect is reduced,
androgen deficiency contributes to enlarge the size of visceral fat
because of increased lipid accumulation in adipocytes, which in turn
causes cellular death followed by macrophage activation, cytokine
production, and endothelial dysfunction. NF-κB role in this process is
depicted (see text). AGT angiotensinogen, FFAs free fatty acids, ICAM-1
intracellular adhesion molecule-1, IL-6 interleukin-6, IL-1β interleukin-1
beta, JNKs c-Jun N-terminal kinases,M1macrophages macrophages that
encourage inflammation, p38 MAPK/MPK/ERK mitogen-activated
protein kinases/extracellular signal-regulated kinases pathway, MCP-1
monocyte chemoattractant protein-1, MIP-1 macrophage inflammatory
protein-1, NF-kB nuclear factor-kappa light-chain-enhancer of activated
B cells, SIRT1 NAD-dependent deacetylase Sirtuin-1, TNFα tumor
necrosis factor-alpha, VCAM-1 vascular cell adhesion protein-1
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ICAM1andVCAM1, aswell as the reduced expression of TNFα,
IL-1β, IL-6,MIP-1α, andMCP-1 in NEMO-deficient endothelial
cells, [66] support the finding that NF-kB signaling contributes to
the development of vascular damage. Moreover, it has been sug-
gested that NF-kB targets mediate lipid ingestion by macrophage
scavenger receptors and foam cell biogenesis [62••].
Interestingly, the AR is also an NF-κB target gene [67••].
Although many authors have considered the AR gender relat-
ed contribution to adipose tissue to be pathophysiological and
cardiovascular risks, there is still much to understand about its
cross-talk with NF-kB signaling pathway. The relationship
between AR and NF-kB might explain at least in part the
pathophysiological mechanism by which androgen dysregu-
lation contributes to the development and progression of met-
abolic syndrome and hypertension.
Conclusions
All data we have discussed suggest a similar effect of andro-
gens on increasing the risk of hypertension in both men and
women. Androgen deficiency, by increasing visceral obesity
and contributing to adipocyte and endothelial dysfunction,
seems to be a major determinant of the increased prevalence
of hypertension in men but also in women particularly in the
postmenopausal period when the protective effect of estrogens
has ended. Molecular mechanisms are unclear but increased
activation of NF-Kb in a state of reduced occupation of AR
may be an important pathway involved in the pathogenesis of
the endothelial dysfunction. The NF-kB signaling may also
suppress brown adipogenesis leading to the enlargement of
white adipocytes. Many more studies will be necessary to
clarify themolecular mechanisms linking androgen deficiency
with the increased risk of hypertension.
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